In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)

PHASE4CompletedINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

September 29, 2018

Study Completion Date

December 19, 2019

Conditions
Malaria
Interventions
DRUG

Coartem™ (Artemether-lumefantrine combination)

AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.

DRUG

Winthrop™ (Amodiaquine-artesunate combination)

AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.

Trial Locations (6)

1902

Centro de Investigaçao em Saude de Manhiça, Manhiça

Unknown

Hospital Rural de Montepuez, Montepuez

Hospital Distrital da Massinga, Massinga

Hospital Distrital de Moatize, Moatize

Hospital Distrital de Mopeia, Mopeia

CP1929

Centro de Investigação em Saúde de Manhiça, Manhiça

All Listed Sponsors
collaborator

United States Agency for International Development (USAID)

FED

lead

Centro de Investigacao em Saude de Manhica

OTHER

NCT04370977 - In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III) | Biotech Hunter | Biotech Hunter